Krystal Biotech (Krystal Biotech) Growth Rank : 0 (As of Jun. 08, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Krystal Biotech Growth Rank?

Krystal Biotech has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Krystal Biotech Growth Rank Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech (Krystal Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (NAS:KRYS) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

Executives

Krish S Krishnan	director, 10 percent owner, officer: President and CEO	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Suma Krishnan	director, 10 percent owner, officer: Chief Operating Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Catherine Mazzacco	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Daniel Janney	director	PO BOX 7414, JACKSON WY 83002
Andrew C. Orth	officer: Chief Commercial Officer	2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Kathryn Romano	officer: Chief Accounting Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Dino A Rossi	director	61 WATROO POINT, DANIEL ISLAND SC 29492
Everett Rand Sutherland	director	29 HARTWELL AVENUE, LEXINGTON MA 02421
Christopher Mason	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Jing L. Marantz	director	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Jennifer Chien	officer: Chief Commercial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
R Douglas Norby	director	C/O MAGNACHIP SEMICONDUCTOR, INC., 20400 STEVENS CREEK BOULEVARD, SUITE 370, CUPERTINO CA 95014
Sun Pharma (netherlands) B.v.	10 percent owner	POLARISAVENUE 87, 2132 JH HOOFDDORP P7 00000